TCTMD’s Top 10 Most Popular Stories for August 2017
Big hits this month were ESC Congress 2017 coverage as well as a feature article on 3-D printing in structural heart disease, among other news.
Breaking news from the European Society of Cardiology (ESC) Congress 2017—from DETO2X-AMI, COMPASS, and CANTOS, among other trials—topped the charts on TCTMD this month, as did Managing Editor Shelley Wood’s preview ahead of the meeting. Other hits were a feature article on 3-D printing in structural heart disease, news that one company is scrapping its bioresorbable scaffold program, and a study exploring the use of fibrinolytic agents for STEMI.
You can check out all our ESC Congress 2017 coverage here.
Don’t waste time with oxygen. Focus instead on getting patients to the cath lab as quickly as possible, says one expert.
The trial “should change guidelines for the management of chronic stable coronary artery disease,” Eugene Braunwald says.
The Barcelona attack just 9 days before the Congress opened left organizers hastening to insist that the show must go on and big trials were still in the offing.
The fast-evolving technology is poised to shake up cardiac interventions, but training, guidelines, reimbursement, and regulatory oversight lag behind.
Signals of harm warrant further study, but experts seem excited at the idea of exploring hitherto unmapped pathways in CVD progression.
In SPYRAL HTN-OFF MED, more intensive denervation lowered blood pressure, warranting larger, more definitive trials, experts say.
The thinner-strut Renuvia scaffold won’t be studied any further based on discouraging results Abbott’s Absorb BVS, the company confirmed.
The findings might help guide development of systems of care in the developing world, one expert says.
The RE-DUAL PCI findings provide a compelling reason to move away from traditional triple therapy with warfarin, Spencer King says.
The updated recommendations, designed to be reader-friendly, emphasize radial access and complete revascularization, among other changes.